Narasin

DB11432

small molecule experimental vet_approved

Deskripsi

Narasin is an agent with coccidiostatic and antibacterial properties.

Struktur Molekul 2D

Berat 765.038
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

55 Data
Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Narasin.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Narasin.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Narasin.
Dicoumarol The risk or severity of bleeding can be increased when Narasin is combined with Dicoumarol.
Phenindione The risk or severity of bleeding can be increased when Narasin is combined with Phenindione.
Warfarin The risk or severity of bleeding can be increased when Narasin is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Narasin is combined with Phenprocoumon.
Acenocoumarol The risk or severity of bleeding can be increased when Narasin is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Narasin is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Narasin is combined with Coumarin.
(R)-warfarin The risk or severity of bleeding can be increased when Narasin is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Narasin is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of bleeding can be increased when Narasin is combined with Fluindione.
Clorindione The risk or severity of bleeding can be increased when Narasin is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Narasin is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Narasin is combined with Tioclomarol.
(S)-Warfarin The risk or severity of bleeding can be increased when Narasin is combined with (S)-Warfarin.
Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Narasin.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Narasin.
Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Narasin.
Lidocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Narasin is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Narasin is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Narasin is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Narasin is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Narasin is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Narasin is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Narasin is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Quinisocaine.
Cisatracurium Narasin may increase the neuromuscular blocking activities of Cisatracurium.
Ambroxol The risk or severity of methemoglobinemia can be increased when Narasin is combined with Ambroxol.
Fecal microbiota The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Narasin.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 3289887
    Behr KP, Luders H, Glunder G, Friederichs M: Narasin poisoning in turkeys. Dtsch Tierarztl Wochenschr. 1988 Mar;95(3):107-8, 110-1.
  • PMID: 3202044
    Salyi G, Szabo E, Bago G, Banhidi G, Szilagyi M: Narasin poisoning in turkeys. Acta Vet Hung. 1988;36(1-2):107-15.
  • PMID: 4060134
    Litjens JB: A case of narasin poisoning in turkeys. Tijdschr Diergeneeskd. 1985 Sep 1;110(17):665.
  • PMID: 8496896
    Van Halderen A, Bastianello SS, Fourie N, Zumpt IF: An outbreak of narasin poisoning in swine. J S Afr Vet Assoc. 1993 Mar;64(1):43-6.
  • PMID: 7839570
    Salles MS, Lombardo de Barros CS, Barros SS: Ionophore antibiotic (narasin) poisoning in rabbits. Vet Hum Toxicol. 1994 Oct;36(5):437-44.
  • PMID: 3222193
    Jeffers TK, Tonkinson LV, Camp LJ, Murphy CN, Schlegel BF, Snyder DL, Young DC: Field experience trials comparing narasin and monensin. Poult Sci. 1988 Jul;67(7):1058-61.
  • PMID: 3222191
    Jeffers TK, Tonkinson LV, Callender ME: Anticoccidial efficacy of narasin in battery cage trials. Poult Sci. 1988 Jul;67(7):1043-9.
  • PMID: 4019361
    Hussey RL, Macy TD, Moran J, Loh A: Liquid chromatographic determination of narasin in feed premixes. J Assoc Off Anal Chem. 1985 May-Jun;68(3):417-8.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Monteban (veterinary)

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul